A Clinical Study to Assess Sutacimig in Participants With Congenital Factor VII Deficiency

Phase 2 Recruiting 18 enrolled Hemab ApS

Non-randomizedSequentialOpen-labelTreatment

Summary

Open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of a single dose of sutacimig monotherapy in participants with congenital FVII deficiency (FVIID).

Timeline

Start: 2026-03-11
Primary completion: 2026-07
Completion: 2026-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sutacimig	Monoclonal antibody	—	Subcutaneous

A Clinical Study to Assess Sutacimig in Participants With Congenital Factor VII Deficiency

Summary

Timeline

Drugs

Indications